eClinical Technology and Industy News

Lucence Announces Publication of Validation Study for LiquidHALLMARK ctDNA Liquid Biopsy Assay

The study, published in PLOS ONE, establishes LiquidHALLMARK’s market-leading sensitivity and identifies actionable biomarkers in majority of cancer patients and 70% of lung cancer patients; Mary Jo Mullen joins the Company as SVP, Commercial to oversee US market growth

Excerpt from the Press Release:

ALO ALTO, Calif.–(BUSINESS WIRE)–Lucence, the precision oncology company pioneering ultrasensitive liquid biopsy tests, is announcing the recent publication of a study validating its LiquidHALLMARK ctDNA liquid biopsy assay in PLOS ONE, a peer-reviewed, open access scientific journal. The study results establish high sensitivity, specificity, accuracy and precision of LiquidHALLMARK, based on the AmpliMark amplicon-sequencing platform, and support compelling clinical applications for its use.

“In the lab and in the real-world, LiquidHALLMARK’s performance is market-leading. We are truly excited about what this means for patients—and the potential to expand access to non-invasive testing that can drive earlier detection, treatment selection, and monitoring for everyone,” said Min-Han Tan, Founding CEO and Medical Director at Lucence.

Analytical validation using reference genetic materials demonstrated a sensitivity of 99.38% for point mutations and 95.83% for insertions/deletions at 0.1% variant allele frequency (VAF), and a sensitivity of 91.67% for gene fusions at 0.5% VAF. Orthogonal comparison of EGFR variant calls made by LiquidHALLMARK and a reference allele-specific PCR method for 355 lung cancer specimens revealed an overall concordance of 93.80%. External validation with cobas® EGFR Mutation Test v2 for 50 lung cancer specimens demonstrated an overall concordance of 84.00%, with a 100% concordance rate for EGFR variants above 0.4% VAF.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?